Skip to main content

Transforming the understanding
and treatment of mental illnesses.

Studies Recruiting Only Men

Mental disorders affect women and men differently — some disorders are more common in men or may be characterized by different symptoms in men and women. Learn more about men and mental health.

Featured Studies

Featured studies include only those currently recruiting participants. Studies with the most recent start date appear first.


Developing mHealth to Promote PrEP Use Among Thai Young Men Who Have Sex With Men

Study Type: Interventional
Start Date: February 23, 2022
Eligibility: Males, 16 Years to 25 Years, Accepts Healthy Volunteers
Location(s): Institute of HIV Research and Innovation, Bangkok, Thailand; Rainbow Sky Association of Thailand, Bangkok, Thailand

The goal of this study is to develop and pilot test technology-based interventions to promote Pre-exposure Prophylaxis (PrEP) uptake and adherence among Thai young men who have sex with men (YMSM).


Addressing the Continuum of Care Among High-risk Thai Men

Study Type: Interventional
Start Date: November 27, 2021
Eligibility: Males, 15 Years to 29 Years, Accepts Healthy Volunteers
Location(s): M-Health Office Ubon, Ubon Ratchathani, Thailand; M-Health Office Maha Sarakham, Maha Sarakham, Thailand

Young Thai men who have sex with men (YMSM) are at high risk for HIV. However, the Thailand National HIV Strategy does not adequately cover HIV prevention for YMSM using specific methods relevant to them, and instead uses a one-size-fits all approach. Partnering with the Thailand Ministry of Public Health (MOPH), the proposed study seeks to finalize, implement and evaluate a multicomponent, multi-level, community mobilization, combination intervention (HUG-M+) to address the entire Continuum of Prevention and Care. The investigators propose to test the efficacy of this approach by conducting research in two Northeastern Thai cities, one randomized to the intervention condition, which will receive HUG-M+ and the other to the control condition, where standard of care will be provided. If HUG-M+ is found to be efficacious, it might be scaled up, with the support of the MOPH, to other regions in Thailand, elsewhere in Asia and the US.


Parrying the Pitfalls of PrEP: Project PEACH

Study Type: Interventional
Start Date: November 20, 2021
Eligibility: Males, 18 Years to 29 Years, Does Not Accept Healthy Volunteers
Location(s): PRISM Research Center, Atlanta, Georgia, United States

The study is a prospective cohort of young Black MSM who are followed for 2 years either in-person at the PRISM Health Research Clinic and/or virtually with telehealth study visits. Follow-up visits occur as frequently as every 3 months, or as appropriate to clinical needs of HIV PrEP or STI PEP. The investigators will enroll men who are not on PrEP at study initiation and who may decide to start or stop PrEP, change from daily oral PrEP to on-demand PrEP or from on-demand PrEP to daily PrEP, and/or start or stop STI PEP at any point in the study period. If there is trouble enrolling men who are not currently on PrEP, the investigators will expand enrollment criteria to include men currently on PrEP. All men will be provided with the study's mobile smart phone app to support early identification of risks for PrEP discontinuation, to provide information about STI PEP and document usage patterns of on-demand PrEP and STI PEP, and to support easy linkage to support services for PrEP counseling and addressing concerns or questions about STI PEP.


Peer-driven Intervention on PrEP

Study Type: Interventional
Start Date: October 8, 2021
Eligibility: Males, 18 Years to 100 Years, Accepts Healthy Volunteers
Location(s): The Miriam Hospital, Providence, Rhode Island, United States

The objective of this study is to seek knowledge of components of an effective peer-driven intervention (PDI) approach assess the feasibility and efficacy of a PDI on PrEP uptake for the purpose of expanding this PDI to promote PrEP in a large scale study.


Testing THRIVE 365 for Black Sexual Minority Men (On The Daily)

Study Type: Interventional
Start Date: September 14, 2021
Eligibility: Males, 16 Years and Older, Accepts Healthy Volunteers
Location(s): Devin English, Newark, New Jersey, United States

The primary goal of this study is to test a minority stress model of psychological health outcomes for Black sexual minority men (BSMM) while using and not using a novel intervention named THRIVE 365. THRIVE 365 combines mHealth and institutional support elements to provide four areas of support for BSMM: 1) Promote HIV and psychological health knowledge and motivation; 2) Foster a sense of community and positive social connections among BSMM; 3) Connect clients to BSMM-affirming healthcare, including HIV treatment and mental healthcare; 4) Provide resources for housing, transportation, and other economic empowerment. To examine the effects of the intervention, we will utilize a 14-day daily diary study to capture daily intervention engagement, HIV and psychological health outcomes, coping, and experiences of racial and sexual minority stressors. We will first examine main associations between intervention engagement and HIV (antiretroviral [ART] use) and psychological health (depressive symptoms, anxiety symptoms, emotion regulation difficulties outcomes) outcomes, then consider how intervention engagement affects coping and attenuates the impacts of racial and sexual minority stressors during the 14 day period.


11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer

Study Type: Interventional
Start Date: August 10, 2021
Eligibility: Males, 18 Years and Older, Does Not Accept Healthy Volunteers
Location(s): University of California San Francisco, San Francisco, California, United States

This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can be useful for detecting certain cell receptor expression in tumor cells in patients with prostate cancer that has spread to other parts of the body (metastatic). 11C-YJH08 is a small-molecule radiotracer that binds to receptors on cells (glucocorticoid receptor) so that they show up better on the PET scan. Anti-hormone therapy (including enzalutamide) can cause more glucocorticoid receptors to be produced in tumor cells, which can make the tumor cells resist hormone therapies. If researchers can find a better way to detect whether glucocorticoid receptors are increasing during therapy, it may lead to more successful therapies using glucocorticoid receptor antagonists.


Enhancing Partner Services Among Men Who Have Sex With Men Living With HIV

Study Type: Interventional
Start Date: August 1, 2021
Eligibility: Males, 18 Years to 99 Years, Does Not Accept Healthy Volunteers
Location(s): Guangzhou Center for Diseases Control and Prevention, Guangzhou, Guangdong, China

Individuals will participate in a pilot randomized controlled trial (RCT) that implements and evaluates the feasibility, acceptability, and effectiveness of crowdsourced partner services (PS) or conventional PS among Chinese men who have sex with men (MSM) living with HIV.

The pilot RCT will include 120 newly identified MSM HIV cases who were born biologically male, aged 18 years old or older, newly identified as HIV positive, had oral or anal sex with a man, had at least one sexual partner in the previous 6 months and live in Guangzhou. Participants will undergo a series of computer-based interviews (baseline and 2 months after enrollment) and will be randomly assigned into two groups in 2:1 ratio (intervention: control) and receive crowdsourced PS and conventional PS, respectively.


Developing Online Interventions to Reduce Stigma-Related Stress, Sexual Health, and HIV Risk Among Young Chinese MSM

Study Type: Interventional
Start Date: April 19, 2021
Eligibility: Males, 16 Years to 30 Years, Accepts Healthy Volunteers
Location(s): Central South University, Hunan, China

This study is a 2-arm RCT that will assess the efficacy of a culturally adapted, 10-session SGM-affirmative, internet-based cognitive behavioral therapy (iCBT) among young men who have sex with men (YMSM) in Hunan province China. The affirmative treatment called ESTEEM is based on a minority stress-focused, CBT framework. In collaboration with colleagues at Central South University (CSU), the investigators will assess whether a culturally adapted version of iCBT ESTEEM demonstrates significant reductions in HIV risk behavior and mental health symptoms (e.g., depression, anxiety) compared to self-monitoring of stress and mood.


Reducing Intersectional Stigma Among High-Risk Women in Brazil to Promote Uptake of HIV Testing and PrEP

Study Type: Interventional
Start Date: December 1, 2020
Eligibility: Males, 18 Years and Older, Accepts Healthy Volunteers
Location(s): CRT - Centro de Referência e Treinamento DST/AIDS, São Paulo, Brazil; SAE - Serviço de Assistência Especializada Campos Elíseos, São Paulo, Brazil

This is a randomized controlled trial of a multi-level intervention to prevent HIV acquisition among transgender women (N=400) in São Paulo, Brazil. The intervention will be evaluated using a randomized wait-list controlled trial to compare uptake of HIV testing (self-testing and clinic-based) (Aim 1), PrEP initiation and persistence (Aim 2), and other prevention services (e.g. harm reduction) among trans women in the intervention arm compared to those in the control arm with data collection scheduled every three-months. Investigators will assess changes in intersectional stigma (Aim 3), including reductions in internalized stigma and increased resilience to anticipated and enacted stigma, among those assigned to intervention compared to those assigned to the control arm, and assess how changes in stigma result in prevention uptake.


Life-Steps Counseling to Enhance Adherence and Engagement in PrEP Care

Study Type: Interventional
Start Date: September 3, 2020
Eligibility: Males, 18 Years and Older, Accepts Healthy Volunteers
Location(s): Fenway Health, Boston, Massachusetts, United States; University of Miami, Miami, Florida, United States

The purpose of this study is to test how different types of interventions may affect how someone takes their pre-exposure prophylaxis (PrEP) medication.


Biomedical HIV/AIDS Prevention Program Yunnan

Study Type: Interventional
Start Date: August 1, 2020
Eligibility: Males, 18 Years and Older, Accepts Healthy Volunteers
Location(s): Yunnan Center for Disease Prevention and Control, Kunming, Yunnan, China

B-HAPPY is an implementation project to study the process by which pre-exposure prophylaxis (PrEP) is introduced and integrated into a specific international health system facing high rates of HIV incidence among men who have sex with men. The study will use a stepped wedge design to compare implementation outcomes across eight municipalities in Yunnan, China.


An Avatar-based Mobile Phone Intervention to Promote Health in African American MSM

Study Type: Interventional
Start Date: March 4, 2020
Eligibility: Males, 18 Years to 34 Years, Does Not Accept Healthy Volunteers
Location(s): University of Illinois at Chicago, Chicago, Illinois, United States

The investigators propose to determine the efficacy of "My Personal Health Guide," a theory-based innovative talking relational human Avatar mobile phone application to engage HIV-positive AAMSM in adherence and retention in care. Providing an empathetic talking Avatar source of HIV-related information, motivation, and behavioral skills that is as private and convenient as their own mobile phone might produce a high impact by overcoming barriers to HIV adherence and retention in care such as stigma and health literacy.


Improving Health Outcomes in Young Cisgender Men and Transgender Women (mLab App)

Study Type: Interventional
Start Date: January 21, 2020
Eligibility: Males, 18 Years to 29 Years, Accepts Healthy Volunteers
Location(s): Lurie Children's Hospital, Chicago, Illinois, United States; Columbia University School of Nursing, New York, New York, United States

The mLab App combines HIV prevention information with push notifications/reminders to complete HIV testing and an automated image processing feature to provide real-time feedback on home-based HIV test results. Theoretically-guided by the Health Information Technology Usability Evaluation Model (Health-ITUEM), the proposed project will refine and test a next-generation diagnostic intervention delivered on a mobile platform to improve HIV testing and linkage-to-care outcomes among youth living with and at-risk for HIV. Given the pervasiveness, low cost, and convenience of mobile technology, the investigators hope that the App can help achieve the goals of the National HIV/AIDS Strategy in the US by increasing the number of persons living with HIV who know their serostatus, decreasing HIV-related disparities, and ultimately reducing the risk of HIV transmission and acquisition.


A Pragmatic Trial of Two Strategies for Implementing an Effective eHealth HIV Prevention Program (Keep It Up! 3.0)

Study Type: Interventional
Start Date: October 9, 2019
Eligibility: Males, 18 Years to 34 Years, Accepts Healthy Volunteers
Location(s): Northwestern University, Chicago, Illinois, United States

This study evaluates and compares two implementation strategies of an online HIV prevention intervention: Strategy 1 in which community-based organizations apply, and are selected, for funding to deliver Keep It Up! through current HIV testing programs; and Strategy 2 which is a "direct-to-consumer" model where centralized staff at Northwestern University recruit participants nationally through online advertising campaigns and manage engagement.


Pre-exposure Prophylaxis (PrEP) at Home

Study Type: Interventional
Start Date: April 26, 2019
Eligibility: Males, 18 Years to 49 Years, Accepts Healthy Volunteers
Location(s): MetroHealth, Cleveland, Ohio, United States; Washington University AIDS Clinical Trial Unit, Saint Louis, Missouri, United States; Open Arms Health Care Center, Jackson, Mississippi, United States; The Fenway Institute, Boston, Massachusetts, United States; Emory University, PRISM Health, Atlanta, Georgia, United States

This study is a randomized clinical trial of PrEP@Home, a home care system for Human Immunodeficiency Virus (HIV) Pre-Exposure Prophylaxis (PrEP). Individuals entering into PrEP care at an initial in-person study visit will be randomized to the PrEP@Home system for home-based PrEP care follow-up visits or to the control standard of care for clinic-based follow-up visits. The primary aim of this study is to assess protective levels of PrEP medication for the intervention arm compared to the control arm.


eTest: Real-time, Remote Monitoring System for Home-based HIV Testing Among High-risk Men Who Have Sex With Men

Study Type: Interventional
Start Date: January 23, 2019
Eligibility: Males, 18 Years and Older, Accepts Healthy Volunteers
Location(s): Brown University School of Public Health, Providence, Rhode Island, United States

The proposed research will conduct a fully-powered efficacy trial of this approach in areas with large populations of AA and H/L MSM and high HIV incidence: Jackson, MS, Los Angeles, CA, and Boston, MA. High-risk MSM who have not tested for HIV in the last year will be recruited from MSM-oriented "hook-up" mobile apps, and assigned to receive either (1) HBST with post-test phone counseling/referral ("eTEST" condition), (2) "standard" HBST without active follow-up, or (3) reminders to get tested for HIV at a local clinic ("control" condition) at three month intervals over the course of 12 months. The investigators will explore the impact of the eTEST system on key outcomes, including rates of HIV testing, receipt of additional HIV prevention services, and PrEP initiation, compared with standard HBST or clinic-based testing reminders alone. The investigators will also explore the cost effectiveness of the eTEST system under various scenarios compared with relying on traditional, clinic-based testing alone.


Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Study Type: Observational
Start Date: July 31, 2010
Eligibility: Males, 18 Years to 55 Years, Accepts Healthy Volunteers
Location(s): Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut, United States

The aim of the present study is to assess the availability of cannabinoid receptors (CB1R) in the human brain. CB1R are present in everyone's brain, regardless of whether or not someone has used cannabis. The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand OMAR, in healthy individuals and several conditions including 1) cannabis use disorders, 2) psychotic disorders, 3) prodrome of psychotic illness and 4) individuals with a family history of alcoholism, 5) Post-Traumatic Stress Disorder 6) Opioid Use Disorder using the PET imaging agent or radiotracer, [11C]OMAR. This will allow us to characterize the number and distribution of CB1R in these conditions. It is likely that the list of conditions will be expanded after the collection of pilot data and as new data on cannabinoids receptor function and psychiatric disorders becomes available.

Those in the cannabis us disorder arm of the study will have a PET scan on at least three occasions: once while smoking as usual, once after 48-hours of abstinence from cannabis, and a final time after 4 weeks of abstinence. Additional scans may be conducted within the 4 weeks and the last scan may be conducted well beyond 4 weeks. Similarly, while most schizophrenia patients may get scanned just once, a subgroup of patients may get scanned more than once. For example to tease out the effects of medications, unmedicated patients may get scanned while unmedicated and again after treatment with antipsychotic medications. Similarly prodromes may get scanned while in the prodromal stage off medications, on medications and after conversion to schizophrenia.